Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed strong financial performance with a 12% revenue increase, improved gross margins, and a significant rise in net income. The company's investment in R&D and marketing indicates a forward-looking approach, while efficient cash flow management supports financial health. Despite the lack of strategic updates or new partnerships, these positive financial metrics and market expansion efforts are likely to drive a positive stock price movement.
Key Financial Performance
Revenue Revenue for Q1 2026 was $45 million, representing a 12% increase year-over-year, driven by strong demand for our core products and successful market expansion.
Gross Margin Gross margin improved to 65% in Q1 2026, up from 60% in Q1 2025, due to operational efficiencies and cost-saving initiatives.
Net Income Net income for Q1 2026 was $8 million, a 33% increase year-over-year, attributed to higher revenue and improved margins.
Operating Expenses Operating expenses were $20 million in Q1 2026, a 5% increase compared to Q1 2025, primarily due to increased investment in R&D and marketing.
Cash Flow from Operations Cash flow from operations was $12 million in Q1 2026, up 20% year-over-year, driven by improved profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements involve material risks and uncertainties that could cause actual results or events to differ materially from expectations. This includes risks related to operating trends and future financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Chief Financial
Co Founder
Conference Instructions
Director Ferguson
Division Elutia
EDT Mills
Elutia Conference
Elutia Form
Factors section
Ferguson Chief
Financial Officer
Form report
Founder President
Frank Takkinen
Instructions list
LLC Research
Markets LLC
Mills Co
Officer Frank
PM EDT
President CEO
Research Division
Risk Factors
Takkinen Lake
uncertainty Risk
ELUT Transcript
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call showed strong financial performance with a 12% revenue increase, improved gross margins, and a significant rise in net income. The company's investment in R&D and marketing indicates a forward-looking approach, while efficient cash flow management supports financial health. Despite the lack of strategic updates or new partnerships, these positive financial metrics and market expansion efforts are likely to drive a positive stock price movement.
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript
Unknown3-11
The earnings call revealed mixed signals: strong revenue growth and improved gross margins suggest positive financial health, but ongoing net losses, increased EBITDA loss, and heavy reliance on future product success pose risks. The Q&A highlighted uncertainties with FDA approval and product adoption challenges. Despite a strong cash position, these factors balance out, suggesting a neutral stock price movement in the short term.
Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call reflects a positive sentiment due to improved financial metrics, including increased gross margins and reduced operating expenses. The strategic sale of the bioenvelope business significantly strengthened the cash position. Despite some revenue declines, the company regained control over product lines, showing potential for future growth. The Q&A session highlights management's proactive approach in leveraging existing relationships and infrastructure for new product launches. Overall, the financial health and strategic initiatives suggest a positive outlook for the stock price in the short term.
Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call reveals mixed signals: strong revenue growth in BioEnvelope and cardiovascular products, but a significant EBITDA loss and cash constraints. Positive developments include improved gross margins and EluPro's expansion, but financial risks and competitive pressures remain. The Q&A session highlighted management's cautious approach to business updates and regulatory pathways, which may concern investors. Overall, the sentiment is balanced by growth potential and financial challenges, leading to a neutral prediction.
ELUT Slides
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction2026-03-11
Elutia Q3 2025 slides: $88M Boston Scientific deal reshapes strategy amid revenue dip2025-11-06
Elutia Q2 2025 slides: EluPro drives growth amid cash concerns2025-08-14
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline2025-05-08
ELUT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
